Investopedia
05 Jan 2026, 13:01 UTC · 38w ago
Verdict
Headline leans bullish. We score ZBIO −0.90 across five claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.90strongly bearish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Zenas BioPharma shares plummeted 55% after a Phase 3 trial for obexelimab failed to secure milestone payments from Royalty Pharma.
More negative than 99% of claims this week
Novo Nordisk launched the Wegovy pill in the US with a starting price of $149 per month for self-pay patients.
Continue reading
5 related stories
More negative than 89% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 93% of claims this week
Bitcoin rose above $94,000 and crypto-linked stocks like COIN and MSTR gained 4% following the US capture of Nicolás Maduro.
More positive than 79% of claims this week
Comcast's spin-off Versant (VSNT) saw shares drop from an open of above $45 to close at $40.57 on its trading debut.
More negative than 76% of claims this week
The typical American timeframe to save for a home down payment fell to seven years in 2025, down from 12 years in 2022.
More positive than 54% of claims this week
Which stocks this story touches
More negative than 89% of ticker scores this week
Shares plummeted 55% despite positive clinical trial results due to investor reaction and milestone payment issues.
More negative than 84% of ticker scores this week
Shares fell sharply on their trading debut following the spin-off.
More positive than 83% of ticker scores this week
Shares gained 4% following the U.S. debut of the Wegovy pill.
More positive than 78% of ticker scores this week
Stock rose at least 4% following an increase in Bitcoin prices.
More positive than 78% of ticker scores this week
Stock rose at least 4% following an increase in Bitcoin prices.
Near neutral — 92% of ticker scores this week are stronger
The company completed a planned spin-off, but the article does not detail a financial impact on the parent.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
7h ago
More positive than 37% of relationship scores this week
[mutual] Zenas BioPharma and Royalty Pharma Investments have a Royalty Purchase Agreement involving milestone payments tied to clinical trials.
−22.4%
Price agrees with the score
$26.76 vs $34.50 close before publication (Jan 2) · not market-adjusted
ZBIO chart →
